Files U.S.

Files U.S. Patent Application for

Ness Ziona, May 8, 2018, CollPlant (NASDAQ:CLGN

, TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair

products (recombinant human, "rhCollagen"), announced that it has filed a provisional patent application with the U.S.

Patent and Trademark Office (USPTO) for photocurable dermal fillers comprised of rhCollagen and hyaluronic acid, for the aesthetics

Yehiel Tal, CollPlant's Chief

Executive Officer, noted, "This application to the USPTO represents an integral part of the Company's strategy to expand

the uses for its novel, rhCollagen-based BioInk into new, high value markets. The combination of hyaluronic acid, a naturally-occurring,

moisture-binding compound, with CollPlant's plant-based, tissue regenerating rhCollagen, is intended to form the basis for

a new dermal filler product line aimed at addressing the need for healthier,' more innovative aesthetic products to

treat wrinkles. Utilization of photocuring technology is expected to simplify the filler administration process and enable an even

more effective treatment."

CollPlant is a regenerative medicine company

focused on 3D bioprinting of tissues and organs, and on the development and commercialization of tissue repair products for orthobiologics

and advanced wound care markets. The Company's products are based on its rhCollagen (recombinant human collagen), which is

produced with CollPlant's proprietary plant-based genetic engineering technology. CollPlant's products address indications

for diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. The Company's flagship

rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs, and the unique Vergenix line of rhCollagen

products includes a soft tissue repair matrix to treat tendinopathy and a wound repair matrix to promote a rapid optimal healing

of acute and chronic wounds.

For more information about CollPlant,

visit http://www.collplant.com

Safe Harbor Statement

This press release may include forward-looking

statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives

plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that

Collplant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized

by terminology such as "believes," "hopes," "may," "anticipates," "should,"

"intends," "plans," "will," "expects," "estimates," "projects,"

"positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light

of management's experience and perception of historical trends, current conditions, expected future developments and other

factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks

and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many

factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated

in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses

and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's

expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on

its rhCollagen based Bioink, VergenixSTR, and VergenixFG; the Company's ability to obtain favorable pre-clinical and clinical

trial results; regulatory action with respect to rhCollagen based BioInk, VergenixSTR, and VergenixFG including but not limited

to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope

of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based BioInk,

VergenixSTR, and VergenixFG; the Company's ability to establish sales and marketing capabilities or enter into agreements

with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain

strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all

aspects of its product manufacturing; the scope of protection we are able to establish and maintain for intellectual property rights

and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall

global economic environment; the impact of competition and new technologies; general market, political, and economic conditions

in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company's strategy;

and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting Collplant is contained

under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the

SEC, and in other filings that Collplant has made and may make with the SEC in the future. The forward-looking statements contained

in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to

future events, and Collplant does not undertake and specifically disclaims any obligation to update or revise any forward-looking

statements, whether as a result of new information, future events or otherwise.